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Abstract
Breast cancer is the most frequently
diagnosed malignancy in women in
the United States. It is the second most
common malignancy to cause death,
with approximately 39,000 women
dying of breast cancer in the United
States in 2013.
Triple negative breast cancer is
defined as the absence of estrogen,
progesterone and human epidermal
growth factor receptor 2 receptors. It
has been associated with a higher
incidence in African American women,
a younger age and a more advanced
stage at diagnosis, and an inferior
overall survival.
To recognize the differences of our
West Virginia community population
when compared to the national
average, we conducted a retrospective
review of all patients diagnosed with
breast cancer from 2000-2012.

Introduction
Breast cancer is the most
frequently diagnosed malignancy in
women in the United States.1 There
were 232,340 women diagnosed
with breast cancer in 2013. This
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accounts for 29% of new cancer
cases. It is the second most
common malignancy causing death
with 39,620 women dying of breast
cancer in the United States in 2013.2
A breast cancer tumor is
characterized by the presence or
absence of the estrogen receptor
(ER), progesterone receptor (PR),
and/or human epidermal growth
factor receptor 2 (HER2). These
biomarkers have a predictive and
prognostic value in the course of
treatment. Triple negative breast
cancer (TNBC) is defined as the
absence of all three receptors and
accounts for 10-20% of the newly
diagnosed breast cancers globally.3
Triple negative breast cancer
has also been associated with
racial disparities. African American
women are found to have a higher
incidence of TNBC when compared
to Caucasian and Hispanic women
(OR 2.98, 95% CI 2.12-4.20).4-5
Women diagnosed with triple
negative disease tend to be of
younger age (34% were 18–29
years of age), lower socioeconomic
status, and are more obese when
compared to hormone positive
tumors (ER/PR+, HER2 negative).4-5
Triple negative tumors have been
found to have distinct features when
compared to non-triple negative
cancers including: larger in size,
higher nodal positivity, higher
advanced stages, more lymphovascular invasion and higher
percentages of poorly differentiated
tumors.5-6 These tumors have also
been shown to have an inferior
cancer-specific and overall survival
(OS) with the highest risk of death
within the first two years after
diagnosis (breast cancer-specific
survival: HR 8.30; 95% CI, 6.2311.05) (OS: HR 6.10; 95% CI, 4.817.74).7 Women with triple negative
tumors are more likely to have higher
rates of visceral metastases, brain
metastases, lung and loco-regional

West Virginia Medical Journal

metastases, but have been found
less likely to have bone metastases.7
To understand the differences of
our Tri-State community population
(West Virginia and it’s neighboring
states Kentucky and Ohio)
compared to the national average,
we conducted a retrospective
review of all patients diagnosed
with breast cancer from 20002012. Our goal was to assess the
differences and survival outcomes
between triple negative breast
cancer and all other types of
hormone positive disease in our
community-based hospital practice.

Methods and Data Review
This is a retrospective chart review
of patients diagnosed with breast
cancer at Marshall University/Cabell
Huntington Hospital from 2000-2012.
The purpose was to assess the
differences in survival and stage
at diagnosis among hormone
positive (ER/PR positive), HER2
positive, Triple Positive (ER/PR/
HER2 + and ER/HER2 +), and
Triple Negative disease (ER/PR/
HER2 negative) in a 12 year period.
Patient information was accessed
through our hospital Breast Cancer
Registry Database. Data collected
included tumor hormone status, age
of the patient at diagnosis, race,
family history of breast cancer,
stage of tumor at diagnosis, date
of diagnosis, year the patient was
deceased or if the patient is still
alive at date of last contact, and
treatment if applicable. Patients with
DCIS, LCIS, missing pathology and
hormone status were excluded.
The time interval between the date
of diagnosis and date of death or
last contact was calculated in days.
Each individual pathology report
was verified for hormone status
and diagnosis of breast cancer.
The patients were divided into 4
groups: Hormone Positive (ER/
PR positive), HER2 positive, Triple

www.wvsma.org
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Table I – Number of Breast Cancer Patients Separated by Hormone Status
Hormone Status

Number of
Patients (%)
N=1022

Hormone Positive (ER or PR Positive)

735 (71.9)

Triple Negative

144 (14.1)

Triple Positive (including ER/HER2 Positive)

88 (8.6)

HER2 Positive

55 (5.4)

Positive, and Triple Negative for
analysis. Patient characteristics were
assessed for stage at diagnosis,
family history of breast cancer,
and survival. Local disease was
defined as Stage I and Stage II,
regional disease as Stage III and
metastatic disease as Stage IV.
Local disease included Stage I and II
disease together due to their similar
treatment regimens, and overall
survival. The primary endpoint
was a two and five year overall
survival by hormone/HER2 receptor
status among the four groups.

Results
This retrospective review included
1,022 patient charts from 2000-

2012 that were diagnosed with
breast cancer at Cabell Huntington
Hospital. Seventy two percent of
the patients were hormone positive
(ER/PR positive), while 14% of the
population was diagnosed with
triple negative disease (Table I).
Seven hundred and ninety patients
presented with local disease (Stage
I+II), 111 with regional disease
(Stage III), 74 with metastatic
disease (Stage IV) and 47 had
missing information. Thirty percent
of the African American population
was diagnosed with triple negative
disease (9/30) in comparison to only
14% of the Caucasian population
(134/983). A large proportion of
African Americans were also

diagnosed with HER2 positive
disease (13%) versus only 5% of
the Caucasian population (Table
II). SEER database information
from 1995-2009 documents that
the incidence rate of breast cancer
was found to be the highest in
the United States in Kentucky
(523.1/100,000 patients) with West
Virginia and Ohio not too far behind
(496.8/100,000 and 470.8/100,000
patients respectively).2
The median age at diagnosis
for triple positive disease was 53
years old, while the median age
at diagnosis for triple negative,
hormone positive and HER2 positive
were 58 years old, 60 years old and
60 years old, respectively. When
comparing our patients to a nearby
facility (West Virginia University WVU), the mean age at diagnosis
was 51.7 years old for the triple
negative hormone group versus
58.2 years old in the other hormone
combination groups.8
Patients in each group reported
a significant family history of
breast cancer in a first degree
relative, ranging from 62% in the
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Table II – Patient Characteristics by Race and Hormone Status
Hormone Status

Caucasian

African
American

Other

P Value

N (%)
Hormone Positive (ER/PR +)

714 (72.6)

14 (46.7)

7 (77.8)

Triple Negative

134 (13.6)

9 (30)

1 (11.1)

Triple Positive (including ER/HER2+)

84 (8.6)

3 (10)

1 (11.1)

HER2 Positive

51 (5.2%)

4 (13.3)

0 (0)

Fisher’s Exact Test =
0.04

Table III – Patients Reporting a Family History of Breast Cancer, Triple Negative vs. Non-Triple Negative
Family History of Breast Cancer

Triple Negative

Non-Triple Negative

Number (%)
Yes

109 (75.7)

60 (68.2)

No

31 (21.5)

22 (25)

Missing

4 (2.8)

6 (6.8)

HER2 positive group to 76% in
the triple negative group. Using a
Pearson Chi-Squared test, patients
presenting with triple negative
breast cancer were compared
to non-triple negative disease
showing no correlation between
family history and the incidence of
TNBC (p value = 0.10) (Table III).
We were unable to identify the
number of patients and their race by
state distribution at our institution.
Data reviewed from WVU also did
not delineate patients by race or
state distribution. The population of
the Tri-State area at our institution
consisted mostly of Caucasian
females (Table II). However, the
rate of African American patients
diagnosed with triple negative
disease was significantly higher
when compared to the Caucasian
population (30% vs. 13.6%,
respectively; p value = 0.04). This
demonstrates that our population of
African American females presented
with a more aggressive disease
subtype at initial diagnosis.
Overall survival (OS) was
evaluated and results adjusted
by stage and hormone/HER2
status (Figure I). Stage IV breast
cancer was associated with the
worst overall survival at just under
25% alive at 5 years (p value
<0.001). Subset analysis revealed
that survival was also drastically
decreased at 2 years for our patients
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diagnosed with Stage IV disease,
either HER2 positive or triple
negative, at time of presentation
(26.7% and 32.3% respectively).
This poor overall survival was in
comparison to all other hormone
groups and existed despite early
diagnosis and early stage at
presentation (p value <0.001 for both
groups) (Figure II). When evaluating
the five year overall survival for
the triple negative disease group
versus all other hormone/HER2
groups with local disease (Stage
I+II) and regional disease (Stage
III), there was a significant decrease
in survival for the TNBC group
at each stage (p value 0.03 and
0.02 respectively) (Figure III).
The unadjusted overall mortality
of triple negative breast cancer
patients when calculated by the Cox
Regression Model was significantly
increased (HR of 1.803, CI 1.289
– 2.52; p = 0.001). When adjusted
for stage and age at diagnosis,
TNBC patients were found to be
2.1 times more likely to die of their
disease when compared to all
other hormone/HER2 groups (p
value < 0.0001; CI 1.455-2.936). In
comparison, triple negative breast
cancer patients studied in the
National Comprehensive Cancer
Network group showed an OS
hazard ratio of 2.72 (p <0.0001)
after adjusting for age, stage,
race and other tumor factors.7
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Pearson Chi Square Test
P = 0.10

Discussion
Triple negative breast cancer
(TNBC) is a challenging clinical
condition. Systemic therapy for these
patients is limited to conventional
chemotherapy due to the lack of
hormone and HER2 receptors. In
this regional retrospective data
analysis, TNBC patients were
compared to non-TNBC patients
to identify the disparities and
outcomes among each group.
Triple negative breast cancer
occurred in 14% of the study
population with a similar rate
reported in another article published
by West Virginia University.8 African
Americans with breast cancer
represented only 3% of our study
population. This demonstrates the
demographic difference of our region
when compared to national data
by the Centers for Disease Control
and Prevention, which reported
that African Americans represent
about 14% of the population with
breast cancer.9 Despite such an
underrepresented population in
this study, TNBC had a higher
prevalence in the African American
group (30% or 9/30) when compared
to other non-triple negative breast
cancer groups. This observation was
consistent with a California cancer
registry review published by Amirikia
et al.10, which revealed that African
Americans developed the highest
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Figure I. Five Year Overall Survival by Stage of Disease at Diagnosis

Figure II. Two Year Overall Survival for Stage IV Disease by Hormone
Group

rate of triple negative disease
when compared to Hispanics and
Caucasians at all age groups.
Contrary to other reports4-5,11, the
women with triple negative disease
in our study had a non-statistically
significant lower median age at
diagnosis when compared to the
hormone positive (ER/PR +) and
the HER2 + only groups (58 years

old and 60 years old, respectively).
Furthermore, triple positive (ER+/
PR+/HER2+ or ER/HER2+) patients
had a median age at diagnosis that
was lower than the TNBC patients
(53 years old versus 58 years old).
When comparing these results to
other institutions in West Virginia,
our triple negative breast cancer
patients are presenting at a later
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age on average when compared to
other women diagnosed with triple
negative breast cancer at other
facilities (58 years old vs. 51.7
years old).8 A probable explanation
for this disparity may be due to the
small sample size of this study.
Family history is a well-known
risk factor for breast cancer. Among
all groups in our study, a positive
family history was reported at
higher rates when compared with
a study by the Collaborative Group
on Hormonal Factors in Breast
Cancer, which reported a family
history of breast cancer between
7-12%.12 The rate of positive family
history of breast cancer in our
triple negative patient population
was 75.7%. Despite having a
significant proportion of patients with
a family history of disease, there
was no correlation between triple
negative disease and a positive
family history as documented by a
Pearson Chi Square test (p=0.10).
BRCA mutational status was not
analyzed due to lack of reporting
in the Tumor Registry database.
Studies by Dent et al and Lin et
al reported a more advanced stage
of disease at diagnosis (i.e Stage
IV) for triple negative breast cancer
patients when compared to other
hormone groups.6-7 Even though
TNBC has been reported to be more
aggressive, our study revealed that
our triple negative breast cancer
population presented at the time of
diagnosis with more local disease
(Stage I+II – 74%) rather than
advanced disease (Stage III or IV –
22%). This finding may be related
to campaigns for breast cancer
screening and good surveillance
by physicians and patients in the
area, especially in those whom
a family history is known.
The two year overall survival in
early stage breast cancer patients
(Stage I+II) was similar among
all hormone positive groups, with
triple negative and HER2 positive
only disease being slightly lower
at 91.6% and 88.5%, respectively.
Multiple reviews have confirmed
that TNBC patients have an overall
inferior outcome.5-7, 10 The Stage IV

September/October 2015 | Vol. 111

33

Original Research Article |

Figure III. Five Year Overall Survival for Local and Regional Disease by
Hormone Group

presented at an earlier stage at time
of diagnosis likely due to effective
screening and patient awareness.
Further studies are warranted
to discover more effective
therapy for this poor outcome
population of breast cancer.
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